Back to Search Start Over

Neural mechanisms of expectancy-based placebo effects in antidepressant clinical trials.

Neural mechanisms of expectancy-based placebo effects in antidepressant clinical trials.

Authors :
Zilcha-Mano S
Wang Z
Peterson BS
Wall MM
Chen Y
Wager TD
Brown PJ
Roose SP
Rutherford BR
Source :
Journal of psychiatric research [J Psychiatr Res] 2019 Sep; Vol. 116, pp. 19-25. Date of Electronic Publication: 2019 May 26.
Publication Year :
2019

Abstract

Background: Patient expectancy of therapeutic improvement is a primary mediator of placebo effects in antidepressant clinical trials, but its mechanisms are poorly understood. This study employed a novel antidepressant trial design, with integrated functional magnetic resonance imaging (fMRI), to manipulate patient outcome expectancy and examine its neural mediators.<br />Method: Twenty-three depressed outpatients, in a randomized controlled trial were assigned to either Open (high outcome expectancy) or Placebo-controlled (low outcome expectancy) treatment with citalopram for eight weeks. fMRI scans were acquired before and after the expectancy manipulation (before medication treatment), while participants performed a masked emotional face task. Focusing on an amygdala region-of-interest (ROI), we tested a model where reduction in amygdala activation mediated outcome expectancy effects on the slope of change in depressive symptoms.<br />Results: Following the manipulation, significant differences between conditions were found in neural activation changes in the amygdala, as well as in superior temporal gyrus, insula, and thalamus. Findings support the proposed mediation model according to which activation in the left amygdala ROI decreased significantly in the Open as opposed to the Placebo-controlled group following randomization (p = 0.009) for sad vs. neutral face contrast. The reduced left amygdala activation, in turn, was a significant predictor of decreased depressive symptoms during the trial (p = 0.007), and the mediation model was significant.<br />Conclusions: Results from this study, the first designed to identify the neural mechanisms of expectancy augmentation in an antidepressant randomized control trial, suggest that therapeutic modulation of amygdala activity may be an important pathway by which patient outcome expectancy influences depressive symptoms. CLINICALTRIALS.<br />Gov Identifier: NCT01919216; Trial name: Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms, URL: https://clinicaltrials.gov/ct2/show/NCT01919216.<br /> (Copyright © 2019 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1879-1379
Volume :
116
Database :
MEDLINE
Journal :
Journal of psychiatric research
Publication Type :
Academic Journal
Accession number :
31176108
Full Text :
https://doi.org/10.1016/j.jpsychires.2019.05.023